<?xml version='1.0' encoding='utf-8'?>
<document id="25823852"><sentence text="In vitro and in vivo drug-drug interaction of losartan and glimepiride in rats and its possible mechanism."><entity charOffset="46-54" id="DDI-PubMed.25823852.s1.e0" text="losartan" /><entity charOffset="59-70" id="DDI-PubMed.25823852.s1.e1" text="glimepiride" /><pair ddi="false" e1="DDI-PubMed.25823852.s1.e0" e2="DDI-PubMed.25823852.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25823852.s1.e0" e2="DDI-PubMed.25823852.s1.e1" /></sentence><sentence text="Losartan and glimepiride are commonly used drugs to treat chronic diseases of hypertension and diabetes; they are both substrates of CYP2C9"><entity charOffset="0-8" id="DDI-PubMed.25823852.s2.e0" text="Losartan" /><entity charOffset="13-24" id="DDI-PubMed.25823852.s2.e1" text="glimepiride" /><pair ddi="false" e1="DDI-PubMed.25823852.s2.e0" e2="DDI-PubMed.25823852.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25823852.s2.e0" e2="DDI-PubMed.25823852.s2.e1" /></sentence><sentence text=" The aim of the present study was to investigate the possible interaction of losartan and glimepiride both in vitro (rat liver microsomes) and in vivo (healthy Sprague-Dawley rats)"><entity charOffset="77-85" id="DDI-PubMed.25823852.s3.e0" text="losartan" /><entity charOffset="90-101" id="DDI-PubMed.25823852.s3.e1" text="glimepiride" /><pair ddi="false" e1="DDI-PubMed.25823852.s3.e0" e2="DDI-PubMed.25823852.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25823852.s3.e0" e2="DDI-PubMed.25823852.s3.e1" /></sentence><sentence text="" /><sentence text="In rat liver microsomes, 1-10 μmol/l losartan and glimepiride were coincubated, and the inhibitory effect was analyzed"><entity charOffset="37-45" id="DDI-PubMed.25823852.s5.e0" text="losartan" /><entity charOffset="50-61" id="DDI-PubMed.25823852.s5.e1" text="glimepiride" /><pair ddi="false" e1="DDI-PubMed.25823852.s5.e0" e2="DDI-PubMed.25823852.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25823852.s5.e0" e2="DDI-PubMed.25823852.s5.e1" /></sentence><sentence text=" In the subsequent pharmacokinetic study, 15 healthy Sprague-Dawley rats received administrations of 5 mg/kg losartan or 1 mg/kg glimepiride or a coadministration"><entity charOffset="109-117" id="DDI-PubMed.25823852.s6.e0" text="losartan" /><entity charOffset="129-140" id="DDI-PubMed.25823852.s6.e1" text="glimepiride" /><pair ddi="false" e1="DDI-PubMed.25823852.s6.e0" e2="DDI-PubMed.25823852.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25823852.s6.e0" e2="DDI-PubMed.25823852.s6.e1" /></sentence><sentence text="" /><sentence text="In the rat liver microsome system, glimepiride showed a slight inhibition of losartan at concentrations of 1-10 μmol/l, whereas losartan exhibited no inhibitory effect on glimepiride"><entity charOffset="35-46" id="DDI-PubMed.25823852.s8.e0" text="glimepiride" /><entity charOffset="77-85" id="DDI-PubMed.25823852.s8.e1" text="losartan" /><entity charOffset="128-136" id="DDI-PubMed.25823852.s8.e2" text="losartan" /><entity charOffset="171-182" id="DDI-PubMed.25823852.s8.e3" text="glimepiride" /><pair ddi="false" e1="DDI-PubMed.25823852.s8.e0" e2="DDI-PubMed.25823852.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25823852.s8.e0" e2="DDI-PubMed.25823852.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25823852.s8.e0" e2="DDI-PubMed.25823852.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25823852.s8.e0" e2="DDI-PubMed.25823852.s8.e3" /><pair ddi="false" e1="DDI-PubMed.25823852.s8.e1" e2="DDI-PubMed.25823852.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25823852.s8.e1" e2="DDI-PubMed.25823852.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25823852.s8.e1" e2="DDI-PubMed.25823852.s8.e3" /><pair ddi="false" e1="DDI-PubMed.25823852.s8.e2" e2="DDI-PubMed.25823852.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25823852.s8.e2" e2="DDI-PubMed.25823852.s8.e3" /></sentence><sentence text=" In vivo, glimepiride did not modify the plasma concentration of losartan and its metabolite E-3174"><entity charOffset="10-21" id="DDI-PubMed.25823852.s9.e0" text="glimepiride" /><entity charOffset="65-73" id="DDI-PubMed.25823852.s9.e1" text="losartan" /><entity charOffset="93-99" id="DDI-PubMed.25823852.s9.e2" text="E-3174" /><pair ddi="false" e1="DDI-PubMed.25823852.s9.e0" e2="DDI-PubMed.25823852.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25823852.s9.e0" e2="DDI-PubMed.25823852.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25823852.s9.e0" e2="DDI-PubMed.25823852.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25823852.s9.e1" e2="DDI-PubMed.25823852.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25823852.s9.e1" e2="DDI-PubMed.25823852.s9.e2" /></sentence><sentence text=" The alteration of an increased AUC and Cmax was observed in the pharmacokinetic parameters of glimepiride and hydroxy glimepiride"><entity charOffset="95-106" id="DDI-PubMed.25823852.s10.e0" text="glimepiride" /><entity charOffset="111-130" id="DDI-PubMed.25823852.s10.e1" text="hydroxy glimepiride" /><pair ddi="false" e1="DDI-PubMed.25823852.s10.e0" e2="DDI-PubMed.25823852.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25823852.s10.e0" e2="DDI-PubMed.25823852.s10.e1" /></sentence><sentence text="" /><sentence text="Glimepiride did not affect losartan pharmacokinetics in rats, while losartan potently altered glimepiride metabolism; this result was inconsistent with the in vitro outcome"><entity charOffset="0-11" id="DDI-PubMed.25823852.s12.e0" text="Glimepiride" /><entity charOffset="27-35" id="DDI-PubMed.25823852.s12.e1" text="losartan" /><entity charOffset="68-76" id="DDI-PubMed.25823852.s12.e2" text="losartan" /><entity charOffset="94-105" id="DDI-PubMed.25823852.s12.e3" text="glimepiride" /><pair ddi="false" e1="DDI-PubMed.25823852.s12.e0" e2="DDI-PubMed.25823852.s12.e0" /><pair ddi="false" e1="DDI-PubMed.25823852.s12.e0" e2="DDI-PubMed.25823852.s12.e1" /><pair ddi="false" e1="DDI-PubMed.25823852.s12.e0" e2="DDI-PubMed.25823852.s12.e2" /><pair ddi="false" e1="DDI-PubMed.25823852.s12.e0" e2="DDI-PubMed.25823852.s12.e3" /><pair ddi="false" e1="DDI-PubMed.25823852.s12.e1" e2="DDI-PubMed.25823852.s12.e1" /><pair ddi="false" e1="DDI-PubMed.25823852.s12.e1" e2="DDI-PubMed.25823852.s12.e2" /><pair ddi="false" e1="DDI-PubMed.25823852.s12.e1" e2="DDI-PubMed.25823852.s12.e3" /><pair ddi="false" e1="DDI-PubMed.25823852.s12.e2" e2="DDI-PubMed.25823852.s12.e2" /><pair ddi="false" e1="DDI-PubMed.25823852.s12.e2" e2="DDI-PubMed.25823852.s12.e3" /></sentence><sentence text=" The mechanism requires further investigation" /><sentence text=" In clinical settings, attention should be paid to the interaction of these two drugs in the human body as well as the possible adverse reactions of glimepiride"><entity charOffset="149-160" id="DDI-PubMed.25823852.s14.e0" text="glimepiride" /></sentence><sentence text="" /></document>